Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
Baxter
Harvard Business School
Johnson and Johnson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Litigation Details for Millennium Pharmaceuticals Inc. v. Sandoz Inc. (D. Del. 2012)

See Plans and Pricing

« Back to Dashboard

Millennium Pharmaceuticals Inc. v. Sandoz Inc. (D. Del. 2012)

Docket   Start Trial Date Filed 2012-08-02
Court District Court, D. Delaware Date Terminated 2018-02-28
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ACCORD HEALTHCARE INC.; ACTAVIS INC.; ACTAVIS LLC; MILLENNIUM PHARMACEUTICALS INC.; SANDOZ INC.
Patents 5,780,454; 6,713,446; 6,958,319
Attorneys Adam Wyatt Poff; Christine M. Cochran; Gary E. Hood; Jack B. Blumenfeld; James F. Hurst; Jason James Rawnsley; John C. Phillips , Jr.; Kathleen B. Barry; Mark T. Deming; Mary T. McCarthy; Maryellen Noreika; Megan C. Haney; Pamela Avallone; Raymond Perkins; Robyn H. Ast-Gmoser; Steven J. Fineman
Firms Morris, Nichols, Arsht & Tunnell; Phillips, Goldman & Spence, P.A.; Phillips, Goldman, McLaughlin & Hall, P.A.; Richards, Layton & Finger, PA; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Millennium Pharmaceuticals Inc. v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Millennium Pharmaceuticals Inc. v. Sandoz Inc. (D. Del. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-08-02 1 8. United States Patent No. 6,713,446 ("the '446 patent"), entitled "Formulation…VELCADEĀ® prior to the expiration of U.S. Patent Nos. 6,713,446 and 6,958,319. … INFRINGEMENT OF U.S. PATENT NO. 6,713,446 17. Plaintiff incorporates… 1. This is an action for patent infringement under the patent laws of the United States, Title… 9. United States Patent No. 6,958,319 ("the '319 patent"), entitled "Formulation External link to document
2014-11-03 122 STIPULATION of Dismissal Regarding U.S. Patent No. 6,958,319 (Accord) by Millennium Pharmaceuticals Inc… 28 February 2018 1:12-cv-01011 830 Patent None District Court, D. Delaware External link to document
2014-11-03 123 STIPULATION of Dismissal Regarding U.S. Patent No. 6,958,319 (Actavis) by Millennium Pharmaceuticals … 28 February 2018 1:12-cv-01011 830 Patent None District Court, D. Delaware External link to document
2014-11-03 124 STIPULATION of Dismissal Regarding U.S. Patent No. 6,958,319 (Sandoz) by Millennium Pharmaceuticals Inc… 28 February 2018 1:12-cv-01011 830 Patent None District Court, D. Delaware External link to document
2015-08-20 148 2 9. U.S. Patent No. 5,780,454 ("the '454 patent"), among others, is also… '454 patent as the "Adams patent" because the number is similar to the patent-in-suit. …its own prior art patent affirmatively claims. Millennium's patent-the Adams patent-specifically teaches…20, 31, 49, and 53 of U.S. Patent No. 6,713,446 ("the '446 patent"). 1 (D.I. 1. 2 ) The… on May 3, 2017. The '454 patent is prior art to the '446 patent and is of record in the prosecution External link to document
2015-08-20 149 Opinion: 1. The asserted claims of U.S. Patent No. 6,713,446 are invalid due to obviousness; 2. The defendants… 28 February 2018 1:12-cv-01011 830 Patent None District Court, D. Delaware External link to document
2015-08-24 150 finding that the asserted claims of U.S. Patent No. 6,713,446 are invalid due to obviousness. (CASE CLOSED… 28 February 2018 1:12-cv-01011 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Harvard Business School
Johnson and Johnson
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.